We have:

--Large cap.

--Two new blockbuster drugs on the way (dibetes and safer blood thinner Plavix competitor)

--Underpriced by about $20

--Excellent call options premiums.

--Excellent dividend.

--Beats esitmates --
Surprise % +7.6% 15.7% 15.8% 6.8% 12.9% +17% +20.9% <-Most recent SEVEN consecutive quarters.

--Huge number of ongoing FDA trials and European trials in progress.

--Owner of a major vaccine company that benefits from absolute necessity by nature of the business

--227 trials under recruitment not including those under the Medimmune business unit

--Over $6.00 earnings on a $45 stock that should be over $60 even without the two new blockbusters high in the pipeline. With those two blockbusters we may be looking at closer to $80 stock.